TrialThe oncologist2019

Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.

Elisabeth Heath et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.